Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Parathyroid surgery for inherited syndromes

Tina WF Yen, MD, MS
Tracy S Wang, MD, MPH
Section Editor
Sally E Carty, MD, FACS
Deputy Editor
Wenliang Chen, MD, PhD


Primary hyperparathyroidism (HPT) is a disorder of the parathyroid glands in which one or more of the glands secrete an excess amount of parathyroid hormone. Although most commonly a sporadic disease, primary HPT can be a part of an inherited genetic syndrome in a small subset of patients. These inherited syndromes include multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), hyperparathyroid-jaw tumor syndrome (HPT-JT), and familial isolated hyperparathyroidism (FIHPT). An inherited form of HPT should be suspected in younger patients, especially those with multiglandular disease, and those with a family history of an endocrinopathy that is known to be associated with HPT [1].

Parathyroid surgery for the treatment of inherited syndromes will be reviewed here. The inherited syndromes are discussed in detail elsewhere. (See "Multiple endocrine neoplasia type 1: Treatment" and "Approach to therapy in multiple endocrine neoplasia type 2" and "Pathogenesis and etiology of primary hyperparathyroidism", section on 'Familial hyperparathyroidism'.)


The indications for parathyroidectomy are the same for patients with either sporadic or inherited forms of primary hyperparathyroidism (HPT) [2-16]. Parathyroidectomy is required to treat HPT in symptomatic patients (eg, nephrolithiasis) and is the preferred treatment in asymptomatic patients who meet the Fourth International Workshop on Asymptomatic Primary Hyperparathyroidism criteria (table 1). (See "Primary hyperparathyroidism: Management", section on 'Candidates for surgery'.)

In addition, the potential benefits of parathyroidectomy should be discussed with MEN1 patients who have severe, medically refractory peptic ulcer disease or other symptoms due to a gastrinoma (ie, the Zollinger-Ellison syndrome). Hypercalcemia worsens hypergastrinemia, which can exacerbate peptic ulcer disease. Successful parathyroidectomy may reduce gastrin secretion [14,17]. (See "Multiple endocrine neoplasia type 1: Treatment", section on 'Indications for surgery' and "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis".)


Surgical approaches to patients with inherited hyperparathyroidism (HPT) vary depending upon their individual syndromes [8]. The principles of parathyroid surgery, however, remain the same.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Dec 2017. | This topic last updated: Feb 27, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2018 UpToDate, Inc.
  1. Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3570.
  2. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.
  3. Herfarth KK, Bartsch D, Doherty GM, et al. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 1996; 120:966.
  4. Mortenson MM, Evans DB, Lee JE, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. J Am Coll Surg 2008; 206:888.
  5. Raue F, Kraimps JL, Dralle H, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995; 238:369.
  6. Evans DB, Rich TA, Cote GJ. Surgical management of familial hyperparathyroidism. Ann Surg Oncol 2007; 14:1525.
  7. Akerström G, Stålberg P. Surgical management of MEN-1 and -2: state of the art. Surg Clin North Am 2009; 89:1047.
  8. Stålberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg 2009; 33:2234.
  9. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003; 138:409.
  10. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15:531.
  11. Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism-jaw tumour syndrome. J Intern Med 2003; 253:634.
  12. Mizusawa N, Uchino S, Iwata T, et al. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 2006; 65:9.
  13. Sharma J, Weber CJ. Surgical therapy for familial hyperparathyroidism. Am Surg 2009; 75:579.
  14. Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987; 102:958.
  15. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.
  16. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.
  17. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247:501.
  18. Versnick M, Popadich A, Sidhu S, et al. Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism. Surgery 2013; 154:101.
  19. Prichard RS, O'Neill CJ, Oucharek JJ, et al. Is focused minimally invasive parathyroidectomy appropriate for patients with familial primary hyperparathyroidism? Ann Surg Oncol 2012; 19:1264.
  20. Lambert LA, Shapiro SE, Lee JE, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg 2005; 140:374.
  21. Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 2003; 134:858.
  22. Goudet P, Cougard P, Vergès B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Néoplasies Endocriniennes Multiples Study Group. World J Surg 2001; 25:886.
  23. Hubbard JG, Sebag F, Maweja S, Henry JF. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 2006; 141:235.
  24. Hellman P, Skogseid B, Oberg K, et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery 1998; 124:993.
  25. O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 1993; 114:1031.
  26. Udelsman R, Åkerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3595.
  27. Yen TW, Wang TS. Subtotal parathyroidectomy for primary hyperparathyroidism. Endocr Pract 2011; 17 Suppl 1:7.
  28. Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med 1995; 238:269.
  29. Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 2007; 246:1075.
  30. Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 2014; 156:1326.
  31. Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg 2011; 35:1993.
  32. Burgess JR, David R, Greenaway TM, et al. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 1999; 134:1119.
  33. Powell AC, Alexander HR, Pingpank JF, et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery 2008; 144:878.
  34. Burgess JR, Giles N, Shepherd JJ. Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2001; 55:689.
  35. Rizzoli R, Green J 3rd, Marx SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 1985; 78:467.
  36. Burgess JR, David R, Parameswaran V, et al. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 1998; 133:126.
  37. Dotzenrath C, Cupisti K, Goretzki PE, et al. Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg 2001; 167:173.
  38. Thompson GB, Grant CS, Perrier ND, et al. Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Arch Surg 1999; 134:699.
  39. Kivlen MH, Bartlett DL, Libutti SK, et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 2001; 130:991.
  40. Casanova D, Sarfati E, De Francisco A, et al. Secondary hyperparathyroidism: diagnosis of site of recurrence. World J Surg 1991; 15:546.
  41. Feldman AL, Sharaf RN, Skarulis MC, et al. Results of heterotopic parathyroid autotransplantation: a 13-year experience. Surgery 1999; 126:1042.
  42. Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Recurrent hyperparathyroidism due to parathyroid autografts: incidence, presentation, and management. Am Surg 1993; 59:178.
  43. Mallette LE, Blevins T, Jordan PH, Noon GP. Autogenous parathyroid grafts for generalized primary parathyroid hyperplasia: contrasting outcome in sporadic hyperplasia versus multiple endocrine neoplasia type I. Surgery 1987; 101:738.
  44. Wells SA Jr, Farndon JR, Dale JK, et al. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg 1980; 192:451.
  45. Melck AL, Carty SE, Seethala RR, et al. Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy. Surgery 2010; 148:867.
  46. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:5644.
  47. VanderWalde LH, Haigh PI. Surgical approach to the patient with familial hyperparathyroidism. Curr Treat Options Oncol 2006; 7:326.
  48. van Heerden JA, Kent RB 3rd, Sizemore GW, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes. Surgical experience. Arch Surg 1983; 118:533.
  49. Philip M, Guerrero MA, Evans DB, et al. Efficacy of 4D-CT preoperative localization in 2 patients with MEN 2A. J Surg Educ 2008; 65:182.
  50. Iacobone M, Masi G, Barzon L, et al. Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 2009; 394:817.
  51. Mehta A, Patel D, Rosenberg A, et al. Hyperparathyroidism-jaw tumor syndrome: Results of operative management. Surgery 2014; 156:1315.
  52. Tonelli F, Marcucci T, Giudici F, et al. Surgical approach in hereditary hyperparathyroidism. Endocr J 2009; 56:827.
  53. Perrier ND, Villablanca A, Larsson C, et al. Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism. World J Surg 2002; 26:907.
  54. Cetani F, Pardi E, Ambrogini E, et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 2006; 64:146.
  55. Iacobone M, Barzon L, Porzionato A, et al. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery 2007; 142:984.
  56. Sarquis MS, Silveira LG, Pimenta FJ, et al. Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 2008; 143:630.
  57. Miccoli P, Barellini L, Monchik JM, et al. Randomized clinical trial comparing regional and general anaesthesia in minimally invasive video-assisted parathyroidectomy. Br J Surg 2005; 92:814.
  58. Carling T, Donovan P, Rinder C, Udelsman R. Minimally invasive parathyroidectomy using cervical block: reasons for conversion to general anesthesia. Arch Surg 2006; 141:401.
  59. Pintaric TS, Hocevar M, Jereb S, et al. A prospective, randomized comparison between combined (deep and superficial) and superficial cervical plexus block with levobupivacaine for minimally invasive parathyroidectomy. Anesth Analg 2007; 105:1160.
  60. Black MJ, Ruscher AE, Lederman J, Chen H. Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: what are the advantages? Ann Surg Oncol 2007; 14:744.
  61. Allendorf J, DiGorgi M, Spanknebel K, et al. 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg 2007; 31:2075.
  62. Taylor J, Fraser W, Banaszkiewicz P, et al. Lateralization of parathyroid adenomas by intra-operative parathormone estimation. J R Coll Surg Edinb 1996; 41:174.
  63. Ito F, Sippel R, Lederman J, Chen H. The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg 2007; 245:959.
  64. Perrier ND, Ituarte P, Kikuchi S, et al. Intraoperative parathyroid aspiration and parathyroid hormone assay as an alternative to frozen section for tissue identification. World J Surg 2000; 24:1319.
  65. Wells SA Jr, Ellis GJ, Gunnells JC, et al. Parathyroid autotransplantation in primary parathyroid hyperplasia. N Engl J Med 1976; 295:57.
  66. Tonelli F, Spini S, Tommasi M, et al. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J Surg 2000; 24:556.
  67. Clerici T, Brandle M, Lange J, et al. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. World J Surg 2004; 28:187.
  68. Sugg SL, Krzywda EA, Demeure MJ, Wilson SD. Detection of multiple gland primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Surgery 2004; 136:1303.
  69. Cayo AK, Sippel RS, Schaefer S, Chen H. Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease. Ann Surg Oncol 2009; 16:3450.
  70. Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg 2008; 248:420.
  71. Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999; 126:1139.
  72. Lew JI, Solorzano CC, Montano RE, et al. Role of intraoperative parathormone monitoring during parathyroidectomy in patients with discordant localization studies. Surgery 2008; 144:299.
  73. Jaskowiak NT, Sugg SL, Helke J, et al. Pitfalls of intraoperative quick parathyroid hormone monitoring and gamma probe localization in surgery for primary hyperparathyroidism. Arch Surg 2002; 137:659.
  74. Dackiw AP, Sussman JJ, Fritsche HA Jr, et al. Relative contributions of technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probe detection, and the rapid parathyroid hormone assay to the surgical management of hyperparathyroidism. Arch Surg 2000; 135:550.
  75. Cohen MS, Dilley WG, Wells SA Jr, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 2005; 138:1033.
  76. Herrera M, Grant C, van Heerden JA, Fitzpatrick LA. Parathyroid autotransplantation. Arch Surg 1992; 127:825.
  77. Saxe AW, Spiegel AM, Marx SJ, Brennan MF. Deferred parathyroid autografts with cryopreserved tissue after reoperative parathyroid surgery. Arch Surg 1982; 117:538.
  78. Edis AJ, Linos DA, Kao PC. Parathyroid autotransplantation at the time of reoperation for persistent hyperparathyroidism. Surgery 1980; 88:588.